SEC Form 4	
------------	--

### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

### OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

				.,											
1. Name and Address of Reporting Person* <u>FORREST K MICHAEL</u>				2. Issuer Name and Ticker or Trading Symbol AVI BIOPHARMA INC [ AVII ]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
										Director	10% (	Owner			
(Last) 4575 SW RESH	(First) EARCH WAY	(Middle) Y, SUITE 200		3. Date of Earliest Transaction (Month/Day/Year) 05/19/2009						X Officer (give title Other (specil below) below) Outside Director					
(Street) CORVALLIS	OR	97333		4. If Amendment, Date of Original Filed (Month/Day/Year) 05/21/2009						<ul> <li>Individual or Joint/Group Filing (Check Applicable Line)</li> <li>X Form filed by One Reporting Person Form filed by More than One Reporting</li> </ul>					
(City)	(State)	(Zip)							Person		-				
		Table I - No	n-Derivative S	Securities Acq	uired,	Dis	posed of, o	or Ben	eficially	Owned					
Date			2. Transaction Date (Month/Day/Year)	Execution Date,		action (Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership			
					Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)			
				curities Acqui						owned					
1			(e.g., puts, ca	Ills, warrants,	optiol	15, C	onvertible	secur	ities)						

	(cigi, puis, variants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code ( 8)		5. Numb of Derivati Securiti Acquire (A) or Dispose of (D) (II 3, 4 and	ed nstr.	6. Date Exerci Expiration Dat (Month/Day/Ye	te	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Non- Qualified Stock Option (right to buy)	\$1.1	05/19/2009		A		20,000		05/19/2010 <sup>(1)</sup>	05/19/2019	Common Stock	20,000	\$0 <sup>(2)</sup>	20,000	D	

Explanation of Responses:

1. Vesting: 25% of the shares vest each year from the date of grant with all shares vesting in four years.

2. Price not required on initial report of stock option granted.

#### By: J David Boyle II, Attorney-10/16/2009

in-fact For: K Michael Forrest

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.